K.C. Pharmaceuticals Recalls Leader Ultra Lubricating Eye Drops for Sterility Concerns
K.C. Pharmaceuticals is recalling 163,008 cartons of Leader Ultra Lubricating Eye Drops due to a lack of assurance of sterility. The product was distributed nationwide under multiple brand names.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II due to a lack of assurance of sterility in an ophthalmic product. The source does not report any illnesses, injuries, or deaths.
Plain-English summary
K.C. Pharmaceuticals, Inc. is recalling 163,008 cartons of Leader Ultra Lubricating Eye Drops (Polyethylene Glycol 400, Propylene Glycol). The recall was initiated because of a lack of assurance of sterility in the product. The affected eye drops are sterile high-performance lubricating drops intended to relieve dry and irritated eyes.
The recalled product was distributed nationwide in the United States. It is available under several brand names and distribution channels, including Leader (distributed by Cardinal Health), exchange select (manufactured for military exchanges), Good Sense (distributed by Perrigo Direct Inc.), and Walgreens. Specific lot numbers and expiration dates are listed in the recall details, including lots SU25B01 and SU25N01 with expiration dates in 2027.
Consumers who have purchased these eye drops should stop using them immediately. They should check their lot numbers and expiration dates against the recall information provided by the FDA or the manufacturer. If the product matches the recalled lots, consumers should return it to the place of purchase for a refund or contact the manufacturer for further instructions.
The recalled product
- Product
- LEADER ULTRA LUBRICATING EYE DROPS (POLYETHYLENE GLYCOL 400, PROPYLENE GLYCOL)
- Brand
- LEADER ULTRA LUBRICATING EYE DROPS
- Manufacturer
- K.C. Pharmaceuticals, Inc.
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 163,008
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot: a) SU25B01
- Exp.: 02/28/2027
- b) SU25N01
- Exp.: 11/30/2027
- c) SU25B01
- SU25N01
- SU25N02
- d) SU25B01
- Exp.: 02/28/2027.
UPCs (4)
- 0096295137101
- 0846036008210
- 614299056190
- 311917201672
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEADER ULTRA LUBRICATING EYE DROPS
- HighLeader ultra lubricating eye drops recalled over sterility assurance failure
FDA (Drugs) · 2026-04-08
Same manufacturer · K.C. Pharmaceuticals, Inc.
See all →- SevereGood Sense Eye Drops Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Artificial Tears Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Same hazard · sterility
See all →- SevereCarolina Infusion Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereApothecary Pharma Recalls Tirzepatide Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereApothecary NAD+ Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- HighLeader ultra lubricating eye drops recalled over sterility assurance failure
FDA (Drugs) · 2026-04-08
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Non-Sterile Lubricant Eye Drops Due to Contamination Risk
FDA (Drugs) · 2024-02-14